Steroid Eye Drops in Chronic Central Serous Chorioretinopathy

In this pilot study the effect and safety of the use of steroid eye drops in chronic central serous chorioretinopathy (cCSC) will be evaluated. The study is conducted as a randomized single-blind placebo-controlled trial. Forty patients will be randomized to either steroid eye drops or placebo eye drops. Patients will self-administer the eye drops three times a day for four weeks.

Inclusion Criteria:Male and female patients aged 18 years or olderSubretinal and/or intraretinal fluid for 3 months or longerPatient is able to self-administer eye dropsSevere Chronic Central Serous Chorioretinopathy, with at least one of the following clinical findings are present within the vascular arcades: Cumulative areas (>5 optic disc diameters) of diffuse atrophic RPE alterations visualized on mid-phase FA; Multifocal "hot spots": at least 2 "hot spots" of leakage separated by at least 1 disc diameter of nonhyperfluorescent healthy-appearing retina on mid-phase FA; Diffuse leakage: an area of diffuse fluorescein leakage >1 optic disc diameter on mid-phase FA, without an evident leaking focus; Presence of posterior cystoid retinal degeneration assessed on OCT.Exclusion Criteria:Evidence of other retinal diagnoses: ((History of) exudative age-related macular degeneration, Suspicion of secondary choroidal neovascularization, Polypoidal choroidal vasculopathy, Multifocal choroiditis, Retinal vascular occlusions, Pseudoxanthoma elasticum, Amblyopia, Severe myopia (more than -6 diopters).Pregnant or breastfeeding womenAllergy to topical ophthalmic steroids.Media opacities that prohibit detailed multimodal imaging(BCVA <20/200) (Snellen equivalent)Contraindications for fluorescein angiography or ICG angiography (known allergies especially against shellfish, previous reactions)